Abstract:Background: Although conventional pain relief therapeutics have centered around mu-opioid agonists, these drugs are limited by adverse side effects, including respiratory depression and addiction potential. The ongoing opioid epidemic has galvanized research into novel analgesic therapies with more favorable profiles. New pharmacologic agents have been developed to target neuronal pathways involved in pain sensation. Certain receptors have been recognized to mediate nociceptive transmission, central sensitization, and the development of chronic pain states. Objectives: We conducted a literature review to identify potential targets for novel analgesic therapies. Study design: This study is a narrative review of potential analgesic targets. We characterize their antinociceptive mechanisms of action and evaluate their therapeutic potential. Methods: A systemized search of available literature on novel analgesics was performed. A search was performed through the PubMed database to identify articles with key words of "novel analgesics," "novel non-opioid analgesics," "novel pain targets," and "non-opioid analgesics." Potential drug classes were identified and researched through corresponding keywords, with an emphasis on publications from 2018 to 2020. Older articles were included if frequently referenced by current literature. Results: Potential novel analgesic targets include Nav1.7, Nav1.8, CaV2.2, and transient receptor potential vanilloid-1 (TRPV1) cation channel receptors in the peripheral nervous system. Other approaches disrupt the synthesis of pronociceptive signaling molecules such as nitric oxide, prostaglandin E2, and interleukin-6 (IL-6). Within central pain pathways, modification of kappa-opioid, delta-opioid, N-methyl-D-aspartate, and cannabinoid receptors have been investigated in chronic pain and hyperalgesia models. Recent advances in molecular technology have also presented opportunities to modify protein expression or the cellular genome altogether. Limitations: Several analgesic targets have only demonstrated efficacy in preclinical trials. There are limited data evaluating the long-term safety profiles of therapies further on in development. Conclusions: We provide an overview of potential analgesic therapies in various stages of development, which may become clinically relevant in the near future. Some drugs such as TRPV1 agonists, anti-IL-6, and anti-nerve growth factor antibodies have demonstrated analgesic effect in specific clinical pain states.

mTOR, a New Potential Target for Chronic Pain and Opioid-Induced Tolerance and Hyperalgesia

Opioid Receptor-Triggered Spinal Mtorc1 Activation Contributes to Morphine Tolerance and Hyperalgesia.

Opioid-induced Hyperalgesia in Chronic Pain Management

Increased Methylation of the MOR Gene Proximal Promoter in Primary Sensory Neurons Plays a Crucial Role in the Decreased Analgesic Effect of Opioids in Neuropathic Pain

Nicotine Inhibits Rapamycin-Induced Pain Through Activating Mtorc1/s6k/irs-1-related Feedback Inhibition Loop

Modulation of mTOR Activity by μ‐Opioid Receptor is Dependent upon the Association of Receptor and FK506‐Binding Protein 12

Nicotine inhibits rapamycin-induced pain through activating mTORC1/S6K/IRS-1-related feedback inhibition loop.

Targeting spinal mechanistic target of rapamycin complex 2 alleviates inflammatory and neuropathic pain

Mu-opioid receptor and receptor tyrosine kinase crosstalk: Implications in mechanisms of opioid tolerance, reduced analgesia to neuropathic pain, dependence, and reward

Mtor-Neuropeptide Y Signaling Sensitizes Nociceptors to Drive Neuropathic Pain

The cellular mechanism by which the rostral ventromedial medulla acts on the spinal cord during chronic pain

Mtor and Its Downstream Pathway Are Activated in the Dorsal Root Ganglion and Spinal Cord after Peripheral Inflammation, but Not after Nerve Injury

PD-1: A New Candidate Target for Analgesic Peptide Design

The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence

Noncoding RNAs: Novel Targets for Opioid Tolerance

Small G-Protein Rheb Gates Mammalian Target of Rapamycin Signaling to Regulate Morphine Tolerance in Mice.

Tiam1-mediated maladaptive plasticity underlying morphine tolerance and hyperalgesia

Mu-Opioid Receptor (MOR) Dependence of Pain in Chemotherapy-Induced Peripheral Neuropathy

Shedding Light on the Pharmacological Interactions between μ-Opioid Analgesics and Angiotensin Receptor Modulators: A New Option for Treating Chronic Pain

Small G-Protein Rheb Gates Mtor Signaling to Regulate Morphine Tolerance in Mice

Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies